ArticleFrontiers in medical technology2025
Large animal models of ischemic mitral regurgitation-systematic review and meta-analysis.
Article in Frontiers in medical technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischaemic mitral regurgitation (IMR) is a significant complication of myocardial infarction associated with increased morbidity and mortality. Large animal models are essential for testing novel mitral valve therapies, yet no consensus exists on the optimal infarction strategy to induce IMR. Methods: A systematic review and meta-analysis were conducted to evaluate infarction strategies used to induce IMR in large animal models. Studies were identified through database searches and screened according to predefined inclusion criteria. Subgroups were stratified by infarction strategy. Proportions of IMR development and severity were analysed using a random-effects model, and reporting quality was assessed across studies. Results: Forty-four studies met the inclusion criteria, comprising 869 animals across 52 subgroups. Ethanol injection in select obtuse marginal arteries (EtOH-OMx strategy) yielded the highest rate of IMR development (87%, 95% CI: 79%-96%) with the lowest associated mortality. Ligation of obtuse marginal arteries under cardiopulmonary bypass (CPB-OM2, OM3 and CPB-OMx) demonstrated high mortality and inconsistent IMR severity. Reporting quality was variable, with frequent omissions regarding sex, randomisation, and adverse event documentation. Conclusions: This review identifies the EtOH-OMx strategy as a promising method for inducing IMR in large animal models, demonstrating favourable performance within the limitations of available data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.